Pharmafile Logo
Pharmafocus logo
Advanced Search

COVID-19

Showing 15 posts of 602 posts found.

covid_cell

COVID-19 vaccine eligibility creates challenges for UK pharmacies

October 8, 2025
Medical Communications COVID-19, NHS, pharmacies, vaccinations

Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments despite no longer meeting the …

News
Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

July 29, 2025
Manufacturing and Production, Medical Communications, Research and Development ADHD, COVID-19, NHS Business Services Authority, Psychiatry, antidepressants, antipsychotics, anxiolytics, barbiturate, dementia, hypnotics, mental health

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions in England have reached their …

News
Vaccine image

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19

July 16, 2025
Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …

News
lab

Study links COVID-19 and some vaccines to increased risk of rare neurological condition

June 5, 2025
Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition

An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …

News

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024
Research and Development COVID-19, EMA, Infections and infestations, coronavirus

AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …

News
diana-polekhina-zbsthwt9vlc-unsplash_2

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024
Research and Development AstraZeneca, COVID-19, Immunology, clinical trial

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 pre-exposure prophylaxis treatment, sipavibart (formerly …

News
Vaccine image

Sanofi and Novavex sign exclusive $1.2bn licensing agreement to co-commercialise COVID-19 vaccine and develop flu-COVID-19 vaccines

May 10, 2024
Sales and Marketing COVID-19, COVID-19 vaccine, Immunology, Novatex, Sanofi, flu-COVID-19 vaccine, licensing agreement

French pharma and healthcare company Sanofi and US biotech Novavex, have entered into a co-exclusive licensing agreement for a number …

News
az_vaccine

AstraZeneca withdraws COVID-19 vaccine Vaxzevria

May 9, 2024
Sales and Marketing AstraZeneca, COVID-19, Immunology, thrombosis with thrombocytopenia syndrome

UK-based pharmaceutical company AstraZeneca has announced that is it voluntarily withdrawing its COVID-19 vaccine Vaxzevria due to a drop in …

News

Gilead’s Veklury recommended by NICE for COVID-19 treatment

April 9, 2024
Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …

News

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

January 12, 2024
Medical Communications COVID-19, Infections and infestations, NICE

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …

News
diana-polekhina-zbsthwt9vlc-unsplash_2

Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine

October 5, 2023
Research and Development COVID-19, Immunology, Moderna, clinical trial, influenza, vaccines

Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational combination vaccine against influenza and …

News

ACM Biolabs shares positive results from phase 1 SARS-CoV-2 booster vaccine trial

September 5, 2023
Research and Development ACM Biolabs, COVID-19, Immunology, SARS-CoV-2, Vaccine, clinical trial

ACM Biolabs has announced positive topline results from its phase 1 trial of ACM-001, an adjuvanted booster vaccine for SARS-CoV-2, …

News

The NIH’s RECOVER initiative could lead to the first official treatment for long COVID-19

August 1, 2023
Research and Development COVID-19, Infections and infestations, NIH, clinical trials, long covid

As of 31 July 2023, The National Institutes of Health (NIH) launched the first trials of its ‘Researching COVID to …

News
study_participant_receives_niaid-gsk_candidate_ebola_vaccine

Moderna files for FDA authorisation for updated COVID-19 vaccine

June 23, 2023
Research and Development COVID-19, FDA, Immunology, Moderna, Vaccine

Biotechnology company Moderna has announced that it has completed submission of a regulatory application to the US Food and Drug …

News

FDA approves first oral antiviral to treat adult patients with COVID-19

May 26, 2023
Medical Communications COVID-19, FDA, Infections and infestations, paxlovid

The US Food and Drug Administration (FDA) has announced that it has approved the oral antiviral Paxlovid (nirmatrelvir tablets and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025